The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy
Open accessAbstract
OBJECTIVE—The objective of this study was to evaluate the safety and short-term effect of adding spironolactone to conventional antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor or an angiotensin II receptor blocker (ARB) on albuminuria and blood pressure in type 2 diabetic patients with nephropathy. RESEARCH DESIGN AND METHODS—Twenty-one type 2 diabetic patients with nephropathy were enrolled in a randomized, double-masked, cross-over study. Patients were treated in random order with spironolactone 25 mg once daily and matched placebo for 8 weeks, respectively, in addition to ongoing antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor and/or an ARB. At the end of each treatment period, albuminuria, 24-h ambulatory blood pressure (ABP), and glomerular filtration rate (GFR) were determined. RESULTS—During the addition of placebo, values were as follows: albuminuria (geometric mean [range]) 1,566 [655–7,762] mg/24 h, ABP (mean ± SE) 138 ± 3/71 ± 1 mmHg, and GFR (mean ± SE) 74 ± 6 ml/min per 1.73 m2. During the addition of spironolactone, albuminuria was reduced by 33% (95% CI 25–41) (P < 0.001), fractional clearance of albumin by 40% (24–53) (P < 0.001), and 24-h ABP by 6 mmHg (2–10) for systolic and 4 mmHg (2–6) for diastolic (P < 0.001 for both). The change in albuminuria did not correlate with the change in systolic 24-h ABP (r = 0.19, P = 0.42) or diastolic 24-h ABP (r = 0.01, P = 0.96). Spironolactone treatment induced an insignificant reversible reduction in GFR of 3 ml/min per 1.73 m2 (−0.3 to 6) (P = 0.08). One patient was excluded from the study due to hyperkalemia. Otherwise treatment was well tolerated. CONCLUSIONS—Our study suggests that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedMixed-Effects Models in Sand S-PLUS
Pinheiro, J. C., & Bates, D. M. (2000) · Statistics and Computing · doi:10.1007/978-1-4419-0318-1 · Cited by 11,187
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Self-citationMogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
Multiple Actions of Steroid Hormones—A Focus on Rapid, Nongenomic Effects
Falkenstein, E., Tillmann, H.-C., Christ, M., Feuring, M., & Wehling, M. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01468-6 · Cited by 991
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Self-citationMixed-Effects Models in S and S-PLUS
(2000) · Statistics and Computing · doi:10.1007/b98882 · Cited by 930
A Simple Method for the Determination of Glomerular Filtration Rate
Bröchner-Mortensen, J. (1972) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517209084290 · Cited by 886
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750
Self-citationIbsen, H., Olsen, M. H., Wachtell, K., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlöf, B., Devereux, R. B., de Faire, U., Fyhrquist, F., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000154082.72286.2a · Cited by 562
Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00885.x · Cited by 539
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
(1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00465-1 · Cited by 494
Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy
Rocha, R. (2000) · Endocrinology · doi:10.1210/en.141.10.3871 · Cited by 475
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 5×
“However, albuminuria was reduced in 17 of 20 patients who completed the study, and therefore our study suggests that the antiproteinuric effect is not restricted to patients with aldosterone escape, which has been reported to occur in 40% of patients receiving chronic ACE inhibitor or ARB treatment(11,12).”
BackgroundResultInfluentialProgression of nephropathy in type 2 diabetic patients
Rossing, K., Christensen, P. K., Hovind, P., Tarnow, L., Rossing, P., & Parving, H.-H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00925.x · Cited by 343
Self-citationChrysostomou, A., & Becker, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451215 · Cited by 267
Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L., & Parving, H.-H. (2004) · Diabetologia · doi:10.1007/s00125-004-1542-0 · Cited by 249
Self-citationRossing, K., Jacobsen, P., Pietraszek, L., & Parving, H.-H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2268 · Cited by 225
Self-citationDual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Rossing, K., Christensen, P. K., Jensen, B. R., & Parving, H.-H. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.95 · Cited by 205
Self-citationNongenomic Vascular Action of Aldosterone in the Glomerular Microcirculation
Arima, S., Kohagura, K., Xu, H.-L., Sugawara, A., Abe, T., Satoh, F., Takeuchi, K., & Ito, S. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000083982.74108.54 · Cited by 202
Rossing, P., Hommel, E., Smidt, U. M., & Parving, H. H. (1994) · Diabetologia · doi:10.1007/s001250050140 · Cited by 192
Self-citationSpironolactone prevents early renal injury in streptozotocin-induced diabetic rats
Fujisawa, G., Okada, K., Muto, S., Fujita, N., Itabashi, N., Kusano, E., & Ishibashi, S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00913.x · Cited by 179
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
Epstein, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80115-3 · Cited by 158
Cicoira, M., Zanolla, L., Rossi, A., Golia, G., Franceschini, L., Cabrini, G., Bonizzato, A., Graziani, M., Anker, S. D., Coats, A. J. S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01237-2 · Cited by 137
Sato, A., Hayashi, K., & Saruta, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.029 · Cited by 132
Davies, J. I., Band, M. M., Morris, A. D., & Struthers, A. D. (2004) · Diabetologia · doi:10.1007/s00125-004-1510-8 · Cited by 131
Derkx, F. H. M., Tan-Tjiong, L. H., Wenting, G. J., Boomsma, F., Veld, A. J. M. I. '., & Schalekamp, M. A. D. H. (1983) · Hypertension · doi:10.1161/01.hyp.5.2.244 · Cited by 127
Self-citationDual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
Jacobsen, P. K. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.6.1019 · Cited by 125
Hovind, P. H., Tarnow, L., Rossing, P. R., Carstensen, B., & Parving, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00870.x · Cited by 90
Self-citationAldosterone as a Determinant of Cardiovascular and Renal Dysfunction
Epstein, M. (2001) · Journal of the Royal Society of Medicine · doi:10.1177/014107680109400803 · Cited by 83
Aldosterone in progressive renal disease
Hostetter, T. H., Rosenberg, M. E., Ibrahim, H. N., & Juknevicius, I. (2001) · Seminars in Nephrology · doi:10.1053/snep.2001.26797 · Cited by 39
Epstein, M., Buckalew, V. M., Altamirano, J. H., Roniker, B., Krause, S. L., & Kleiman, J. H. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)81115-9 · Cited by 36
Schjoedt, K. J., Jacobsen, P., Rossing, K., Boomsma, F., & Parving, H. (2005) · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · doi:10.1055/s-2005-861359 · Cited by 35
Self-citation
Cited by
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
Chapman, N., Dobson, J., Wilson, S., Dahlöf, B., Sever, P. S., Wedel, H., & Poulter, N. R. (2007) · Hypertension · doi:10.1161/01.hyp.0000259805.18468.8c · Cited by 629
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Metadata
- Authors
- Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2005-09-01
- Volume
- 28
- Issue
- 9
- Pages
- 2106-2112
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2118932957
- Cited by
- 299
- References
- 44
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.